Questions & evidence

GLP-1 constipation

Constipation appears in the adverse-reaction sections for semaglutide and tirzepatide products, including Ozempic, Wegovy, Mounjaro, and Zepbound. The percentages differ across their study populations and assigned doses. A useful answer to a GLP-1 constipation question therefore starts with the label context, rather than a single number for the whole category. This reference describes the reported data and the limits of comparing it. Ozempic labelWegovy labelMounjaro labelZepbound label

Updated . Sources checked against the cited documents on 19 November 2026.

Semaglutide: two injection evidence sets

Ozempic section 6.1 reports constipation in 5.0% at 0.5 mg and 3.1% at 1 mg, compared with 1.5% on placebo. Those data come from the pooled adult type 2 diabetes monotherapy and basal-insulin studies. Wegovy Table 3 describes a different pool: adult weight-management Studies 2, 3, and 4 using 2.4 mg weekly, with constipation reported in 24% versus 11% on placebo. Ozempic labelWegovy label

Both use the active ingredient semaglutide, but that does not make the study populations or doses interchangeable. Each label notes that study conditions vary widely, so its rates cannot be directly compared with rates in another drug's studies. The four tables also come from different populations and doses. The numbers can be displayed together to identify their provenance, but they cannot establish that one product will produce more or less constipation for an individual reader. Ozempic labelWegovy label

Tirzepatide: retain the brand and study pool

Zepbound pooled Study 1 and Study 2 reported constipation in 17%, 14%, and 11% at 5, 10, and 15 mg, compared with 5% on placebo. The footnote includes hard stools in the category. Mounjaro pooled SURPASS-1 and SURPASS-5 adult diabetes data reported 6%, 6%, and 7% at the same assigned strengths, compared with 1% on placebo. Zepbound labelMounjaro label

These rows represent different evidence sets. The Zepbound percentages decrease across the assigned-dose columns, while the Mounjaro values do not follow the same pattern. Neither pattern supplies a personal dose-adjustment rule. It is more accurate to retain the published group descriptions than to turn a table shape into a prediction about what happens after a medication change. Zepbound labelMounjaro label

Constipation reports: label-defined study pools, not a head-to-head comparison Ozempic labelWegovy labelZepbound labelMounjaro label
Product / study poolDose groupReported / placebo
Ozempic monotherapy + basal insulin0.5 / 1 mg5.0% / 3.1%; placebo 1.5%
Wegovy Studies 2–42.4 mg24%; placebo 11%
Zepbound Studies 1–25 / 10 / 15 mg17% / 14% / 11%; placebo 5%
Mounjaro SURPASS-1 and SURPASS-55 / 10 / 15 mg6% / 6% / 7%; placebo 1%

Frequency does not supply a personal explanation

The label percentages describe reported events during studies. They do not establish how many days a particular episode lasted or why a particular person experienced it. Postmarketing reports are another evidence category, with uncertain population size and limits on estimating frequency or causation. All four labels list severe constipation including fecal impaction, ileus and intestinal obstruction among reports received after approval. A study table and a voluntary-report list should not be presented as the same kind of measurement. Ozempic labelWegovy labelZepbound labelMounjaro label

This page does not infer an individual mechanism, suggest a remedy, or use the presence of constipation as a reason to choose a different amount of medication. Its scope is the label evidence: which population was observed, which amount was assigned, what category was reported, and what the source says about interpretation. Those boundaries keep a factual reference from becoming an unsupported treatment plan.

Keep observations attached to dates

PinPoint supports daily notes and side-effect severity ratings, as well as injection logs with compound, dose, site, and pain level. Backfilling earlier doses can preserve context around a dated observation. These features make a history available for review without claiming that the app can determine the cause of a symptom or diagnose a gastrointestinal condition. App features

The app also supports PDF, CSV, and JSON export. A record can retain the observation as written, the date logged, and the surrounding prescribed phase. The modeled-level graph is an estimate from the half-life value stored for each compound, published where a published value exists and an estimate where none does, not a clinical test. Talk to the prescriber about new, persistent, or concerning constipation. App features

Useful distinctions

Questions

Is constipation listed for both semaglutide and tirzepatide?

Yes. The cited Ozempic, Wegovy, Mounjaro, and Zepbound adverse-reaction sections all report constipation, with different study populations and dose-specific percentages. Ozempic labelWegovy labelMounjaro labelZepbound label

Do the tables tell me which product will cause fewer symptoms?

No. Each label notes that its rates cannot be directly compared with rates in another drug's studies, and the four tables come from different populations and doses. The percentages provide source-specific context rather than a personalized ranking. Ozempic labelWegovy labelMounjaro labelZepbound label

Your record, together

Keep the details attached to the date.

Dose history, reminders, daily notes, and the context you choose to record. PinPoint app features.

Get PinPoint on the App Store

Sources & scope

Label facts link to the full prescribing information. Product claims use the supplied PinPoint app description. Numerical examples show their assumptions and arithmetic.

  1. PinPoint feature description

    Only feature claims verified against the supplied description. No prices, clinical recommendations or inferred tablet inventory.

  2. Mounjaro prescribing information

    2 (schedule/administration), 3 (presentations), 6.1–6.2 (adverse reactions), 14 (study identity), Medication Guide and Instructions for Use. DailyMed set ID: d2d7da5d-ad07-4228-955f-cf7e355c8cc0, DailyMed SPL of 27 August 2026.

  3. Ozempic prescribing information

    2 (schedule/administration), 3 (presentations), 6.1–6.2 (adverse reactions), 14 (study identity), Medication Guide and Instructions for Use. DailyMed set ID: adec4fd2-6858-4c99-91d4-531f5f2a2d79, DailyMed SPL of 1 June 2026.

  4. Wegovy prescribing information

    2 (schedule/administration), 3 (presentations), 6.1–6.2 (adverse reactions), 14 (study identity), Medication Guide and Instructions for Use. DailyMed set ID: ee06186f-2aa3-4990-a760-757579d8f77b, DailyMed SPL of 18 June 2026.

  5. Zepbound prescribing information

    2 (schedule/administration), 3 (presentations), 6.1–6.2 (adverse reactions), 14 (study identity), Medication Guide and Instructions for Use. DailyMed set ID: 487cd7e7-434c-4925-99fa-aa80b1cc776b, DailyMed SPL of 28 August 2026.